[HTML] sciencedirect.com

[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

WL Yeo, GJ Riely, BY Yeap, MW Lau, JL Warner… - Journal of Thoracic …, 2010 - Elsevier
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
被引用次数：89 相关文章

[引用][C] Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

WL Yeo, GJ Riely, BY Yeap, MW Lau… - Journal of Thoracic …, 2010 - cir.nii.ac.jp
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

WL Yeo, GJ Riely, MG Kris, DG Tenen, W Pao… - Cancer Research, 2010 - AACR
Introduction: The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are active in non-
small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene …
[PDF] core.ac.uk

[PDF][PDF] Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

WL Yeo, GJ Riely, BY Yeap, MW Lau… - Journal of Thoracic …, 2010 - core.ac.uk
Purpose: The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-
small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene …

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

WL Yeo, GJ Riely, BY Yeap, MW Lau… - Journal of thoracic …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

WL Yeo, GJ Riely, BY Yeap, MW Lau, JL Warner… - Journal of Thoracic …, 2010 - jto.org
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
[HTML] nih.gov

[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations

WL Yeo, GJ Riely, BY Yeap, MW Lau… - Journal of thoracic …, 2010 - ncbi.nlm.nih.gov
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small-
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

WL Yeo, MW Lau, JL Warner, K Bodio, MS Huberman… - 2010 - scholarbank.nus.edu.sg
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations |
ScholarBank@NUS Skip navigation NUS Repository NUS Libraries NUS Home Research …

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

WL Yeo, GJ Riely, BY Yeap, MW Lau… - Journal of Thoracic …, 2010 - europepmc.org
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

W Yeo, GJ Riely, B Yeap, MW Lau, J Warner… - Journal of Clinical …, 2010 - ascopubs.org
7572 Background: The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in
non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene …